Oncolytics Biotech gets Nasdaq notice for failing $1 minimum bid price rule

• Oncolytics Biotech received a Nasdaq notice for failing the $1 minimum bid price rule after ONCY closed below $1 for 30 straight sessions.
• Shares remain listed on the Nasdaq Capital Market while the company seeks to regain compliance.
• Nasdaq set a 180-day cure window ending Jan. 19, 2027; compliance requires a closing bid of at least $1 for 10 consecutive sessions.
• Failure to cure could trigger delisting risk; a second 180-day extension may be available if other listing standards are met.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001129928-26-000047), on July 24, 2026, and is solely responsible for the information contained therein.